October 18, 2024 07:00 AM EDTUpdated 10:00 AM
Peer Review

Ex­clu­sive: Ex-Af­fimed CEO heads to UK nanomed­i­cine biotech; Ja­mi Ru­bin leaves Bound­less Bio af­ter IPO

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Ayisha Sharma

News Reporter

Adi Hoess de­scribes him­self as some­one who “likes to build” com­pa­nies fo­cused on “chal­leng­ing tech­nolo­gies.” It’s fit­ting, then, that af­ter spend­ing more than a decade …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times